FORBES-TATE — Lobbying Disclosure | Poliscope

FORBES-TATE

View full entity profile (contributions, contracts, SEC) →

Lobbying Income

$244.1M

Filings

5,755

Unique Clients

170

Active Period

2012–2026

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2026	$18,980,000	432	153
2025	$26,790,000	620	170
2024	$28,320,000	654	162
2023	$25,090,000	585	158
2022	$25,460,000	556	148
2021	$24,795,000	594	154
2020	$19,570,000	508	136
2019	$14,775,000	359	93
2018	$12,965,000	297	74
2017	$10,515,000	243	60
2016	$9,655,000	215	55
2015	$8,562,000	194	52
2014	$8,227,000	184	50
2013	$8,190,000	208	66
2012	$2,180,000	106	36

Top Clients

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
OPTIONS CLEARING CORPORATION (OCC)	$5,785,000	56	2013–2026
PHRMA	$4,215,000	54	2013–2026
AMERICAN HONDA MOTOR CO., INC.	$3,920,000	61	2012–2026
NATIONAL CABLE TELECOMMUNICATIONS ASSOCIATION	$3,410,000	59	2012–2026
GENERAL ATOMICS	$3,395,000	58	2012–2026
AMGEN USA, INC.	$3,360,000	54	2013–2026
ENTERGY SERVICES, LLC	$3,125,000	55	2014–2026
CTIA - THE WIRELESSS ASSOCIATION	$2,915,000	54	2013–2026
ASSOCIATION OF AMERICAN RAILROADS	$2,900,000	50	2014–2026
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION	$2,770,000	56	2013–2026
AIRLINES FOR AMERICA	$2,680,000	47	2016–2026
GENENTECH	$2,635,000	54	2013–2026
ORACLE	$2,600,000	40	2013–2023
ANNALY CAPITAL MANAGEMENT, INC.	$2,435,000	35	2013–2021
PACIFIC GAS AND ELECTRIC	$2,415,000	56	2013–2026
ASSURED GUARANTY MUNICIPAL CORP.	$2,400,000	29	2019–2026
UNITED PARCEL SERVICE	$2,390,000	57	2012–2026
BLACKSTONE ADMINISTRATIVE SERVICES PARTNERSHIP L.P.	$2,360,000	26	2020–2026
VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIES	$2,360,000	54	2013–2026
HCR MANORCARE	$2,340,000	40	2013–2022
GILEAD SCIENCES, INC.	$2,280,000	29	2020–2026
T-MOBILE	$2,155,000	60	2012–2026
ALTRIA CLIENT SERVICES LLC	$2,100,000	43	2016–2026
COMCAST CORPORATION	$2,090,000	33	2012–2020
LIVE NATION ENTERTAINMENT, INC.	$2,090,000	29	2019–2026

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	5,092
HOUSE OF REPRESENTATIVES	5,040
Health & Human Services, Dept of (HHS)	292
White House Office	224
Commerce, Dept of (DOC)	131
Agriculture, Dept of (USDA)	120
Environmental Protection Agency (EPA)	115
Interior, Dept of (DOI)	113
U.S. Trade Representative (USTR)	81
Treasury, Dept of	80
Energy, Dept of	71
Homeland Security, Dept of (DHS)	66
Council on Environmental Quality (CEQ)	64
Justice, Dept of (DOJ)	64
Centers For Medicare and Medicaid Services (CMS)	46
Centers For Disease Control & Prevention (CDC)	37
Federal Emergency Management Agency (FEMA)	27
Office of Management & Budget (OMB)	22
Office of Natl Drug Control Policy (NDCP)	22
Substance Abuse & Mental Health Services Administration (SAMHSA)	22

Top Issues Lobbied

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	1,839
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	1,698
Budget/Appropriations	Budget/Appropriations	1,489
Medicare/Medicaid	Medicare/Medicaid	1,044
Environment/Superfund	Environment/Superfund	772
Energy/Nuclear	Energy/Nuclear	759
Trade (domestic/foreign)	Trade (domestic/foreign)	723
Telecommunications	Telecommunications	599
Transportation	Transportation	532
Financial Institutions/Investments/Securities	Financial Institutions/Investments/Securities	448
Defense	Defense	389
Consumer Issues/Safety/Products	Consumer Issues/Safety/Products	377
Agriculture	Agriculture	372
Labor Issues/Antitrust/Workplace	Labor Issues/Antitrust/Workplace	371
Science/Technology	Science/Technology	284
Manufacturing	Manufacturing	260
Government Issues	Government Issues	246
Copyright/Patent/Trademark	Copyright/Patent/Trademark	236
Education	Education	233
Clean Air and Water (quality)	Clean Air and Water (quality)	220

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 22119th Congress

SAVE Act

2026 · third_quarter · Client: VOTER PARTICIPATION CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Client expense: — · Firm income: $30,000

Matched citations: H.R. 22

H.R. 22119th Congress

SAVE Act

2026 · third_quarter · Client: VOTER PARTICIPATION CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Client expense: — · Firm income: $30,000

Matched citations: H.R. 22

H.R. 22119th Congress

SAVE Act

2026 · third_quarter · Client: VOTER PARTICIPATION CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Client expense: — · Firm income: $30,000

Matched citations: H.R. 22

S. 128119th Congress

SAVE Act

2026 · third_quarter · Client: VOTER PARTICIPATION CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Client expense: — · Firm income: $30,000

Matched citations: S. 128

Show 21 more cited filings

S. 128119th Congress

SAVE Act

2026 · third_quarter · Client: VOTER PARTICIPATION CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Client expense: — · Firm income: $30,000

Matched citations: S. 128

S. 128119th Congress

SAVE Act

2026 · third_quarter · Client: VOTER PARTICIPATION CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Client expense: — · Firm income: $30,000

Matched citations: S. 128

H.R. 3633119th Congress

Digital Asset Market Clarity Act

2026 · third_quarter · Client: VISA U.S.A. INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to payments, including in H.R. 7035/S. 3623 - Credit Card Competition Act of 2026; Issues related to the GENIUS Act (P.L. 119-27); Issues related to H.R. 3633 - Digital Asset Market Clarity Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 3633

H.R. 7035119th Congress

Credit Card Competition Act of 2026

2026 · third_quarter · Client: VISA U.S.A. INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to payments, including in H.R. 7035/S. 3623 - Credit Card Competition Act of 2026; Issues related to the GENIUS Act (P.L. 119-27); Issues related to H.R. 3633 - Digital Asset Market Clarity Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 7035

S. 3623119th Congress

Credit Card Competition Act of 2026

2026 · third_quarter · Client: VISA U.S.A. INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to payments, including in H.R. 7035/S. 3623 - Credit Card Competition Act of 2026; Issues related to the GENIUS Act (P.L. 119-27); Issues related to H.R. 3633 - Digital Asset Market Clarity Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 3623

H.R. 5099119th Congress

SAFES Act

2026 · third_quarter · Client: TRACTOR SUPPLY CO.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to Tax Relief for American Families and Workers; Issues related to H.R. 5099 - SAFES Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5099

H.R. 1672119th Congress

Maintaining Investments in New Innovation Act

2026 · third_quarter · Client: NOVARTIS, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1672

H.R. 1672119th Congress

Maintaining Investments in New Innovation Act

2026 · third_quarter · Client: NOVARTIS, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1672

H.R. 3037119th Congress

Access to Breast Cancer Diagnosis Act of 2025

2026 · third_quarter · Client: NOVARTIS, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 3037

S. 1500119th Congress

Access to Breast Cancer Diagnosis Act of 2025

2026 · third_quarter · Client: NOVARTIS, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.

Client expense: — · Firm income: $50,000

Matched citations: S. 1500

S. 832119th Congress

EPIC Act of 2025

2026 · third_quarter · Client: NOVARTIS, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.

Client expense: — · Firm income: $50,000

Matched citations: S. 832

H.R. 4231119th Congress

Treat and Reduce Obesity Act of 2025

2026 · third_quarter · Client: LILLY USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 4231

H.R. 5316119th Congress

Drug Shortage Compounding Patient Access Act of 2025

2026 · third_quarter · Client: LILLY USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5316

H.R. 5316119th Congress

Drug Shortage Compounding Patient Access Act of 2025

2026 · third_quarter · Client: LILLY USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5316

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · third_quarter · Client: LILLY USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6509

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · third_quarter · Client: LILLY USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6509

S. 1973119th Congress

Treat and Reduce Obesity Act of 2025

2026 · third_quarter · Client: LILLY USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Client expense: — · Firm income: $50,000

Matched citations: S. 1973

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · third_quarter · Client: LILLY USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Client expense: — · Firm income: $50,000

Matched citations: S. 3794

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · third_quarter · Client: LILLY USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Client expense: — · Firm income: $50,000

Matched citations: S. 3794

H.R. 2362119th Congress

VA Home Loan Awareness Act of 2025

2026 · third_quarter · Client: BROKER ACTION COALITION

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to H.R. 2362/S. 138 - VA Home Loan Awareness Act of 2025; Issues related to H.R. 3694/S. 1932 - VALID Act of 2025; Issues related to H.R. 6047 - Sharri Briley and Eric Edmundson Veterans Benefits Expansion Act of 2026; Issues related to H.R. 9237/S. 4744 Take Care of America's Veterans Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2362

H.R. 3206119th Congress

Protecting America's Property Rights Act

2026 · third_quarter · Client: BROKER ACTION COALITION

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to H.R. 5508 - Mortgage Insurance Freedom Act; Issues related to H.R. 3206 - Protecting Americas Property Rights Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 3206

Source: Senate LDA